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Abstract
Background: More effective chemotherapies are urgently needed for bladder cancer, a major cause of morbidity
and mortality worldwide. We therefore explored the efficacy of the combination of gemcitabine and AZD7762, a
checkpoint kinase 1/2 (CHK1/2) inhibitor, for bladder cancer.
Methods: Viability, clonogenicity, cell cycle distribution and apoptosis were assessed in urothelial cancer cell lines
and various non-malignant urothelial cells treated with gemcitabine and AZD7762. DNA damage was assessed by
γH2A.X and 53-BP1 staining and checkpoint activation was followed by Western blotting. Pharmacological
inhibition of CHK1 and CHK2 was compared to downregulation of either CHK1 or CHK2 using siRNAs.
Results: Combined use of gemcitabine and AZD7762 synergistically reduced urothelial carcinoma cell viability and
colony formation relative to either single treatment. Non-malignant urothelial cells were substantially less sensitive
to this drug combination. Gemcitabine plus AZD7762 inhibited cell cycle progression causing cell accumulation in
S-phase. Moreover, the combination induced pronounced levels of apoptosis as indicated by an increase in the
fraction of sub-G1 cells, in the levels of cleaved PARP, and in caspase 3/7 activity. Mechanistic investigations
showed that AZD7762 treatment inhibited the repair of gemcitabine-induced double strand breaks by interference
with CHK1, since siRNA-mediated depletion of CHK1 but not of CHK2 mimicked the effects of AZD7762.
Conclusions: AZD7762 enhanced sensitivity of urothelial carcinoma cells to gemcitabine by inhibiting DNA repair and
disturbing checkpoints. Combining gemcitabine with CHK1 inhibition holds promise for urothelial cancer therapy.
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Background
Bladder cancer is a major cause of morbidity and mortality
worldwide, with about 380,000 new cases and 150,000
deaths per year [1]. Unfortunately, treatment of advanced
bladder cancer has progressed little over the past two de-
cades [2]. Combination chemotherapies employing gemci-
tabine plus cisplatin (GC) or methotrexate plus vinblastine,
doxorubicin and cisplatin (MVAC) are the first line stand-
ard regimens for advanced or metastatic bladder cancer [3].
Although the tumours often respond initially, the median
overall survival (OS) of patients with advanced bladder
carcinoma is only approximately 14 months, and median
progression-free survival after cisplatin-based first-line ther-
apy ranges from 7 to 9 months [4]. Furthermore, more than
50% of bladder cancer patients are unfit for cisplatin treat-
ment because of renal dysfunction, a poor performance
status, or comorbidities [5]. For patients ineligible for
cisplatin the European Association of Urology (EAU)
guidelines indicate chemotherapy using carboplatin and
gemcitabine as a first line therapy, but the median OS is
only 9.3 months [6, 7]. Therefore, more effective regimens
avoiding cisplatin are urgently needed.
Genomic instability is a pervasive characteristic of many
cancers, especially invasive urothelial carcinoma, the major
histological subtype of bladder cancer, and DNA damage is
a key factor in the evolution and treatment of cancer [8].
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Upon DNA damage caused by chemotherapy, checkpoints
respond to DNA damage by arresting the cell cycle to pro-
vide time for DNA repair. Checkpoint signalling following
DNA damage is initiated by the proximal kinases, ataxia
telangiectasia mutated (ATM) or ataxia telangiectasia and
RAD3-related (ATR) [9]. ATM is recruited to and activated
primarily at DNA double-strand breaks (DSBs) in conjunc-
tion with the MRE11:RAD50:NBS1 (MRN) sensor complex
[10]. ATR is activated by recruitment to tracts of single
strand DNA (ssDNA), and the ATR-ATRIP (ATR-interact-
ing protein) protein kinase complex is crucial for the cellu-
lar response to replication stress and DNA damage [11].
These kinases subsequently activate the downstream
serine/threonine kinases, checkpoint kinase 1 and 2 (CHK1
and CHK2). The functionally analogous kinases CHK1 and
CHK2 then act as transducers in DNA-damage checkpoint
signalling [12]. Upon activation, CHK1 and CHK2
phosphorylate downstream effectors such as the CDC25
family that further propagate checkpoint signalling, leading
to intra-S phase and G2/M phase arrest [13]. Inhibition of
checkpoint kinases abrogates DNA damage-induced cell
cycle arrest allowing cells to enter mitosis despite the
presence of DNA damage, which can lead to cell death.
Accordingly, AZD7762, a potent CHK1/CHK2 inhibitor,
possesses chemosensitizing activity in vitro and in vivo [14].
However, it remains unknown to which extent AZD7762
may promote chemotherapy-induced tumour cell death in
urothelial cancer cell lines (UCCs).
Gemcitabine is a deoxycytidine analogue that has been
used as a chemotherapeutic agent for more than 15 years.
It disturbs DNA synthesis [15] by inhibition of deoxynu-
cleotide biosynthetic enzymes [16], ultimately inducing
apoptosis [17].
In the current study we investigated whether AZD7762
co-administration is capable of enhancing the toxicity of




The UCCs VM-CUB1, RT-112 and T24 were obtained
from the DSMZ (Braunschweig, Germany); the UM-UC-
3 cell line was kindly provided by Dr. Grossman
(Houston, USA). All UCCs were regularly authenticated
by STR profiling (most recent fingerprint analysis shown
in [18]). A human telomerase reverse transcriptase
(hTERT)-immortalized normal human urothelial cell line
(hTERT-NHUC) [19] was kindly provided by Dr.
Knowles (Leeds, UK). The spontaneously immortalized
human bladder cell line HBLAK was obtained from CELLn-
TEC (Bern, Switzerland). The gemcitabine resistant T24 cell
line variant T24rGEMCI20 [20] was derived from the Resist-
ant Cancer Cell Line (RCCL) collection (www.kent.ac.uk/
stms/cmp/RCCL/RCCLabout.html). UCCs were routinely
maintained in DMEM GlutaMAX-I (Gibco, Life Technolo-
gies, Darmstadt, Germany) supplemented with 10% foetal
calf serum (GE Healthcare, Piscataway, NJ, USA) and for
T24rGEMCI20 cells additionally with 20 ng/ml gemcitabine
(Selleck Chemicals, Munich, Germany). hTERT-NHUC was
cultured in keratinocyte serum-free medium (Gibco, Life
Technologies, Darmstadt, Germany) supplemented with
0.25 ng/mL EGF, 12.5 μg/mL bovine pituitary extract and
1:100 insulin-transferrin-selenium (Gibco, Life Technolo-
gies), 0.35 μg/mL N-epinephrine, and 0.33 mg/mL hydro-
cortisone (Sigma Aldrich, Munich, Germany). HBLAK was
cultured in CnT-Prime Epithelial Culture Medium (CELLn-
TEC). All cells were incubated at 37 °C in a humidified at-
mosphere with 5% CO2.
Reagents and siRNA transfection
Gemcitabine, AZD7762, Gö6976, romidepsin and givino-
stat were purchased from Selleck Chemicals. Gemcitabine
was dissolved in water, all other compounds were dis-
solved in dimethyl sulfoxide (DMSO). Cisplatin solution
was purchased from Accord Healthcare (London, UK).
The reagents were stored at −70 °C until use.
Viability assay
Viability was measured by the NAD(P)H-dependent MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrayolium brom-
ide) dye reduction assay (Sigma Aldrich). Cells were seeded
at a density of 3 × 103 cells per well on 96-well culture
plates, allowed to attach for 24 h, treated with different
concentrations of gemcitabine and/or AZD7762 or other
compounds and incubated for an additional 24 or 48 h, as
indicated.
For siRNA-mediated knockdown, UCCs were transfected
with 10 nmol/L CHK1 and/or CHK2 ON-TARGET plus
Human siRNA or an ON-TARGET plus Non-targeting
Pool siRNA for 24 h using Lipofectamine RNAi MAX
(Invitrogen, Life Technologies, Darmstadt, Germany).
Transfected cells were then harvested, seeded at a density
of 3 × 103 cells per well on 96-well culture plates, allowed
to attach for 24 h, and treated with different concentrations
of gemcitabine for 48 h. Cell viability was evaluated by
MTTassay as described above.
ATP-based cell viability and apoptosis assays
Cell viability was additionally measured via total cellular
ATP as an indicator for viable cells using the CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Mannheim,
Germany). After treatment with different concentrations of
gemcitabine and/or AZD7762, cells were grown for 24 or
48 h and viability was measured by transferring cell aliquots
into 96-well plates using CellTiter-Glo Reagent. Apoptosis
induction after the treatment was quantified by the
caspase-Glo 3/7 assay (Promega) and normalized to the
ATP assay results.
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Colony forming assay and Giemsa-staining
For the colony forming assay, 3 × 103 cells were seeded
per 6 cm plate. After 10 days, cells were washed with PBS
(Biochrom, Merck Millipore, Berlin, Germany), fixed in
methanol, and stained with Giemsa solution (Merck,
Darmstadt, Germany).
Flow cytometry
For flow cytometry to evaluate changes in the cell cycle
and apoptosis, 7.5 × 104 cells were seeded in a 6-well
culture plate 1 day prior to treatment with different con-
centrations of gemcitabine and/or AZD7762 for 24 or
48 h. Then, attached and floating cells were stained with
PI-buffer containing 50 μg/ml propidium iodide, 0.1% so-
dium citrate and 0.1% Triton X-100, and flow cytometry
was performed using a Miltenyi MACSQuant Analyzer
(Milteny Biotec GmbH, Bergisch Gladbach, Germany).
DNA histograms were fitted according to established pro-
tocols [21] using the MACSQuantify software (Miltenyi
Biotec). Intervals for the respective cell cycle phases were
individually configured for each DMSO treated control
sample after 24 and 48 h, respectively, and applied to the
corresponding drug-treated samples.
Immunofluorescence stainings
For immunofluorescence, cells cultured on coverslips were
treated as indicated for 24 or 48 h. Cells were fixed with
4% formaldehyde and permeabilized with 0.3% Triton X-
100 in PBS for 10 min at room temperature (RT). Block-
ing was done in 10% goat serum (DAKO, Glostrup,
Denmark), 0.3 M glycine and 0.1% Triton X100 in PBS for
1 h at RT. The fixed cells were incubated overnight at 4 °C
with the primary antibodies pH2A.X (1:100, Cell Signaling
Technology, Inc., Danvers, MA, USA) and 53-BP1 (1:250,
clone BP18, Merck Millipore). Second antibodies were
Alexa Fluor 488-conjugated goat-anti-rabbit IgG antibody
and TRITC-conjugated goat-anti-mouse IgG (H + C)
(Invitrogen, Life Technology) for 1 h at RT. Nuclei were
counterstained with 500 ng/ml DAPI (4’,6-diamidino-2-
phenylindole) for 5 min before mounting with fluores-
cence mounting medium (DAKO). Samples were imaged
with a Nikon Eclipse 400 microscope.
Western blotting
For western blotting, cells were maintained under the in-
dicated conditions for 24 or 48 h and total protein lysates
were prepared with RIPA-buffer containing 150 mM
NaCl, 1% Triton X-100, 0.5% deoxycholate, 1% Nonidet P-
40, 0.1% SDS, 1 mM EDTA, 50 mM Tris (pH 7.6) and
10 μl/ml protease inhibitor cocktail (Sigma Aldrich) for
30 min on ice. Protein concentrations were determined by
BCA protein assay (Thermo Scientific, Rockford, IL,
USA). Equal amount of proteins were separated by so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis
and transferred to PVDF membranes (Merck Millipore).
Membranes were blocked with 5% bovine serum albumin
or 5% non-fat milk in TBST (150 mM NaCl, 10 mM Tris,
pH 7.4 and 0.1% Tween-20), washed and incubated with
primary antibodies at RT for 1 h or at 4 °C overnight.
Primary antibodies were used against phosphorylated
ATM (Ser1981) (1:10000, Abcam, Cambridge, UK), ATM
(1:1000, Cell Signaling Technology), phosphorylated ATR
(Ser428) (1:1000, Cell Signaling Technology), ATR (1:10
00, Cell Signaling Technology), phosphorylated CHK1
(Ser345) (1:1000, Cell Signaling Technology), CHK1
(1:1000, Cell Signaling Technology), phosphorylated CHK
2 (Thr68) (1:1000, Cell Signaling Technology), CHK2
(1:1000, Cell Signaling Technology), p21CIP1 (1:250, Santa
Cruz Biotechnology, Heidelberg, Germany), poly [ADP-ri-
bose] polymerase 1 (PARP1) (1:1000, Cell Signaling
Technology), cleaved PARP (1:1000, Cell Signaling
Technology), and anti-α-Tubulin B-512 (1:10000, Sigma
Aldrich) or GAPDH (1:10000, Abcam) as loading controls.
Secondary antibodies were HRP-conjugated goat-anti-
mouse antibody and HRP-conjugated goat-anti-rabbit
antibody (1:5000) (Santa Cruz Biotechnology) for 1 h at
RT. Bands were visualised by chemiluminescence with the
ECL select luminescence kit (GE Healthcare, Piscataway,
NJ, USA) or the WesternBright Quantum kit (Biozym,
Hessisch Oldendorf, Germany).
Statistical analysis
Combination indexes (CI) were calculated by the
Chou-Talalay method using CalcuSyn software (Biosoft,
Cambridge, UK).
Results
The combination of gemcitabine and AZD7762
significantly reduced the viability of UCCs
In MTT assays, up to 40 nM AZD7762 had little effect of
its own, but enhanced the effects of gemcitabine on the
viability of four different urothelial carcinoma cell lines.
However, it did not enhance the effect of gemcitabine on
the non-malignant cell lines hTERT-NHUC and HBLAK,
on normal urothelial (UP) cells, or the gemcitabine-
resistant cell line T24rGEMCI20 (Fig. 1a). The com-
bination efficiently inhibited the growth of UCCs in a
dose-dependent manner. Combination index calculation
demonstrated that the combined effect on cell viability of
UCCs was synergistic (CI <1) under most treatment con-
ditions (Table 1).
We then investigated whether the combination of
gemcitabine and AZD7762 also affects the clonogenicity
of urothelial carcinoma cells. The combination treatment
inhibited colony formation almost completely in UCCs
whereas gemcitabine or AZD7762 alone inhibited colony
formation only to a limited extent (Fig. 1b). Thus, the
combination of gemcitabine with AZD7762 efficiently
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inhibited long-term growth of urothelial carcinoma cells
in vitro.
Light microscopic examinations revealed characteristic
morphological changes in UCCs treated with gemcita-
bine and AZD7762. After 24 h of gemcitabine single
treatment or the combination treatment, cell size in-
creased and cells became flatter compared with those
treated with DMSO or AZD7762 alone. Cell structures
were destroyed after 48 h of the combination treatment,
whereas only minor further morphological changes oc-
curred between 24 and 48 h of gemcitabine single treat-
ment (Fig. 1c).
To compare the response of UCCs to sequential vs.
simultaneous treatment, UCCs were pretreated with
AZD7762 for 24 h and then incubated with gemcitabine
for 48 h. Pretreatment with AZD7762 still enhanced the
cytotoxic effect of gemcitabine, but not as strongly as
simultaneous treatment (Additional file 1: Figure S1).
Fig. 1 Viability and clonogenicity of UCCs and non-malignant urothelial cells after treatment with gemcitabine and/or AZD7762. a Relative cell
viability in UCCs (VM-CUB1, RT-112, T24, UM-UC-3), non-malignant human urothelial cells (hTERT-NHU, HBLAK, UP) and T24rGEMCI20 cells was mea-
sured by MTT assay (mean ± SD, n = 4) after 48 h treatment with gemcitabine and/or AZD7762. b Giemsa staining of colonies from UCCs after 24
and 48 h treatments compared to DMSO solvent control. GEM stands for gemcitabine. The concentration of AZD7762 is 10 nM in RT-112 and T24
cells, and 20 nM in VM-CUB1 and UM-UC-3 cells. c Photomicrographs showing characteristic morphological changes in T24 cells treated with
gemcitabine and AZD7762 (24 and 48 h) (c). Scale bar = 100 μm
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MTT assays were also employed to investigate whether
AZD7762 likewise enhanced the activity of cisplatin and
the class I HDAC-specific inhibitors, romidepsin and
givinostat, three agents highly toxic to UC cells. Cisplatin
produces mostly intrastrand DNA cross-links [22].
Pharmacologic inhibition of HDAC1 and HDAC2 by
romidepsin or givinostat severely disrupts cell cycle
progression and likewise induces DNA damage [18].
However, none of these agents acted synergistically with
AZD7762 (Additional file 2: Figure S2a).
AZD7762 enhances gemcitabine activity through CHK1
inhibition
Treatment with gemcitabine or cisplatin, but not with
romidepsin or givinostat strongly enhanced CHK1 phos-
phorylation at Ser345 (Additional file 2: Figure S2b), indi-
cating that the extent of CHK1 phosphorylation does not
predict whether AZD7762 sensitises cells to a DNA-
damaging compound in a synergistic manner.
To investigate the relative contributions of inhibition
of CHK1 or CHK2 to gemcitabine treatment, we used
siRNA to selectively deplete CHK1 or CHK2 from UCC
cell lines. Compared to nonspecific siRNA-treated cells,
CHK1-depleted cells were efficiently sensitised to gemci-
tabine, whereas CHK2-depleted cells were not markedly
sensitised (Fig. 2a, b). Additional depletion of CHK2 in-
creased the sensitisation induced by CHK1 depletion.
These data suggest that sensitisation to gemcitabine by
AZD7762 is mainly mediated by CHK1 inhibition and
CHK2 inhibition has a supplementary role. Accordingly,
pharmacological inhibition of CHK1 by the CHK1-
specific inhibitor Gö6976 also efficiently sensitised T24
cells to gemcitabine (Fig. 2c).
The combination of gemcitabine and AZD7762 causes cell
accumulation in S-phase and apoptosis
To further investigate the mechanisms by which AZD7762
increases the effects of gemcitabine, we analysed cell cycle
distribution and apoptosis induction in response to treat-
ment. After 24 h, UCCs treated with gemcitabine alone or
with the combination displayed accumulation of cells with
S-phase DNA content (Fig. 3a). However, during gemcita-
bine single treatment many cells appeared to overcome this
accumulation after 48 h of treatment. In contrast, cells
treated with gemcitabine and AZD7762 remained accumu-
lated in S phase or underwent apoptosis, as indicated by a
significant increase in the fraction of sub-G1 cells in all cell
lines after 48 h combined treatment, compared with
untreated controls or each single treatment. In the T24 cell
line, the increase in the fraction of sub-G1 cells was re-
markable already after 24 h.
Consistently with the flow cytometry data, Western
blot analysis showed that the expression of cyclin E,
which is maximal in S-phase, was increased after 24 h of
gemcitabine treatment in UCCs but returned to control
levels after 48 h (Fig. 3b). However, when gemcitabine
was combined with AZD7762, its expression remained
elevated after 48 h in VM-CUB1, RT-112, and T24 cells.
The combination of gemcitabine and AZD7762 induced
apoptosis in UCCs
After treatment with different concentrations of gemcita-
bine and/or AZD7762, UCC viability was measured
additionally by assaying ATP. The combination treatment
significantly decreased cell viability in all UCCs (Fig. 4a).
Significantly increased caspase-3/7 activity was observed
after 48 h of combination treatment in all cell lines, most
strongly in RT-112 (Fig. 4b). Accordingly, increased levels
of cleaved PARP were detected by Western blot analysis
following combination treatment (Fig. 4c). In the T24 cell
line, cleaved PARP already increased after 24 h of
treatment, fitting the advanced increase in the sub-G1
fraction in cell cycle analysis. Thus, the combination of
gemcitabine and AZD7762 efficiently induced apoptosis
in all UCCs, albeit with somewhat different time courses.
AZD7762 inhibited DNA damage repair sensitising UCCs
to gemcitabine-induced DNA damage
To investigate the presence of unrepaired double strand
breaks (DSB) induced by gemcitabine and AZD7762, we
assessed colocalisation of double staining for the DSB
markers γH2A.X and 53-BP1 [23] by immunofluores-
cence (Fig. 5a, Additional file 3: Figure S3). As antici-
pated, exposure of UCC cells to gemcitabine elevated
γH2A.X and 53-BP1 focal staining after 24 h of treat-
ment. Staining returned to near control levels after 48 h,
indicating that the DNA DSBs were repaired. Addition
of AZD7762 with gemcitabine increased γH2A.X and
Table 1 Combination indexes
AZD7762 (nM)
Gemcitabine (nM) 10 20 40
VM-CUB1
10 0.427 0.239 0.178
20 0.505 0.408 0.366
RT-112
10 0.277 0.262 0.232
20 0.628 0.628 0.645
T24
10 0.423 0.422 0.369
20 0.762 0.764 0.751
UM-UC-3
10 0.495 0.392 0.343
20 0.725 0.718 0.639
Combination indexes (CI) calculated for the combination of gemcitabine and
AZD7762 in urothelial carcinoma cells (CI < 1 indicates synergy)
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53-BP1 levels after 24 h, and this increase was remark-
ably prolonged until after 48 h. These results indicate
that AZD7762 disturbed gemcitabine-induced DNA
damage repair.
In the T24rGEMCI20 cell line, 10 nM gemcitabine did
not elevate γH2A.X and 53-BP1 foci, whereas 300 nM
concentration, which is much higher than clinically
achievable, led to a sustained increase (Fig. 5b). These
data suggest that the repair of DNA DSBs was delayed
or abrogated in the gemcitabine-resistant cell line at very
high concentrations. We furthermore analysed the re-
sponse to gemcitabine in the T24rGEMCI20 cell line by
Western blot analysis. The ATR-mediated phosphoryl-
ation of CHK1 (Ser345 CHK1) was increased only at the
higher concentration of gemcitabine and likewise sus-
tained after 48 h of treatment (Fig. 5c).
To confirm that AZD7762 inhibits CHK1/CHK2 in
UCCs, CHK1/CHK2 signalling was investigated. UCC
cultures were treated with gemcitabine in the presence
or absence of AZD7762 for 24 and 48 h before harvest-
ing for Western blot analysis (Fig. 6). Ser345 CHK1 was
transiently phosphorylated after 24 h of gemcitabine
treatment returning to near control levels after 48 h.
Ser345 CHK1 phosphorylation was further enhanced
when UCCs were co-treated with AZD7762. ATM
became phosphorylated (at Ser1981) after 24 h of
gemcitabine exposure and ATM phosphorylation was
increased when gemcitabine was combined with
AZD7762. Phosphorylation of CHK2 at Thr68, affected
by activated ATM, was also detected after 24 h of com-
bination treatment. The increased activation of check-
point kinases is consistent with more pronounced DNA
Fig. 2 Effects of siRNA mediated knockdown of CHK1, CHK2 or CHK1/2 on sensitivity to gemcitabine. a Effects of specific CHK1, CHK2, or both
siRNAs compared to control siRNA (irrelevant) on CHK1 and CHK2 protein expression after 48 h transfection in VM-CUB1, RT-112 and T24 cells. b
Effect of gemcitabine on cell viability in VM-CUB1, RT-112 and T24 cell lines after siRNA knockdown of CHK1, CHK2 or both CHK1/2 compared to
irrelevant control. Note that for each siRNA treatment mean viability without gemcitabine was set as 1. c Relative cell viability in RT-112 and T24
cells was measured by MTT assay (mean ± SD, n = 4) after 48 h treatment with gemcitabine and/or Gö6976
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damage upon co-administration of AZD7762 with gem-
citabine. In the RT-112 cell line, ATM and CHK2 phos-
phorylation increased even after 48 h of gemcitabine
single treatment suggesting that gemcitabine-induced
double strand breaks persisted even after 48 h in this
cell line.
Fig. 3 Effects of gemcitabine and AZD7762 on cell cycle distribution. a UCCs were treated for 24 or 48 h with gemcitabine (10 nM) and/or
AZD7762 (10 nM in RT-112 and T24 cells, and 20 nM in VM-CUB1 and UM-UC-3 cells) before cell cycle distribution was analysed by flow cytome-
try. DMSO served as a solvent control. b Cyclin E protein expression subsequent to gemcitabine and/or AZD7762 treatment was evaluated by
Western blot analysis
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Relation of sensitisation by AZD7762 to p21CIP1 expression
In The Cancer Genome Atlas (TCGA) dataset, 14% of
invasive bladder cancers have mutations in CDKN1A
encoding the cyclin-dependent kinase inhibitor p21CIP1
[24]. It was previously reported that double mutant p53/
p21-deficient bladder cancers were more sensitive to
combined treatment with gemcitabine and a CHK in-
hibitor [25]. To examine this further, we performed
Western blot analysis in the four UCCs used in the
current study. Three expressed p21CIP1, whereas RT-112
cells lacked expression (Additional file 4: Figure S4a)
due to a homozygous frame-shift mutation at codon 29
Fig. 4 Analysis of cell death mechanism after treatments. a Relative cell viability in UCCs was measured after treatments with 10 nM gemcitabine and/or
AZD7762 using the CellTiterGlo ATP-assay. The concentration of AZD7762 used was 10 nM in RT-112 and T24 cells, and 20 nM in VM-CUB1 and UM-UC-3
cells. b Induction of apoptosis was measured by caspase 3/7 assay. c Cleaved PARP was measured after the indicated treatments (24 and 48 h)
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Fig. 5 Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X
(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24rGEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm. c
Western blot analysis of S345 CHK1 after treatments with gemcitabine in T24rGEMCI20 cells (24 and 48 h). As loading control, GAPDH was stained
Fig. 6 Western blot analysis of checkpoint factors. Whole cell lysates from UCCs treated with gemcitabine (10 nM) and/or AZD7762 (10 or 20 nM) for
24 or 48 h were assayed for the indicated proteins or their phosphorylation. As loading controls, GAPDH or α-tubulin were stained on each blot
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[26]. As mentioned above, in our hands, AZD7762 sensi-
tised all four UCCs including RT-112 to gemcitabine in a
synergistic fashion, although checkpoint activation by gem-
citabine alone was more pronounced in RT-112. We there-
fore assessed the changes in the expression of p21CIP1.
Expression of p21CIP1 increased in VM-CUB1 cells follow-
ing treatment with gemcitabine or gemcitabine-AZD7762
combination, whereas p21CIP1 remained undetectable in
RT-112 cells, as expected (Additional file 4: Figure S4b).
These data suggest that sensitisation of UCCs to gemcita-
bine by AZD7762 is qualitatively independent of p21CIP1
expression.
Discussion
In the present study, we showed that AZD7762, an ATP
competitive inhibitor of checkpoint kinases, can strongly
sensitise UCCs to the ribonucleotide reductase inhibitor
gemcitabine. The effect of AZD7762 is associated with
abrogation of the G2 checkpoint activation induced by
gemcitabine and especially with persistence of unrepaired
DNA damage, as indicated by our findings that AZD7762
increased ATR-mediated CHK1 phosphorylation (Ser345
CHK1) and that it inhibited the repair of gemcitabine-
induced double strand breaks as evidenced by sustained
expression of γH2A.X and 53-BP1. There are likely several
reasons why AZD7762 leads to persistence of double
strand breaks, including its inhibitory effects on Rad51
focus formation and homologous recombination DNA re-
pair [27] and on the function of CHK1 in the maintenance
of replication forks [28]. The enhancement of cytotoxicity
by AZD7762 was relatively specific to gemcitabine, as the
combination effect was weaker with other compounds
causing DNA strand-breaks, like cisplatin or HDAC1/2
inhibitors (Additional file 2: Figure S2a).
As AZD7762 is an equally potent inhibitor of both
CHK1 and CHK2 [14], a priori, inhibition of both kinases
might contribute to its enhancement of gemcitabine
activity on UCCs. Indeed, CHK2 is also capable of arresting
the cell cycle by several mechanisms [29]. However, siRNA
depletion experiments showed that interference with
CHK1 results in a much more pronounced UCC sensitisa-
tion to gemcitabine compared to interference with CHK2,
but that depletion of both kinases was most efficient.
Therefore, interference with CHK1 is primarily responsible
for UCC sensitisation to gemcitabine. In concordance,
pharmacological inhibition of CHK1 by the CHK1-specific
inhibitor Gö6976 [30] also efficiently sensitised UCCs to
gemcitabine. However, the effects of CHK1 depletion are
further enhanced by additional inhibition of CHK2 activity.
Notably, although CHK1 gene knock-out is lethal in
embryos [31] and induces apoptosis in embryonic stem
cells [32], the depletion of CHK1 by siRNA in somatic cells
on its own has been reported to cause little cytotoxicity
and enhance the efficacy of DNA-damaging drugs in p53-
deficient cancer cell lines [33]. In accordance, we did not
find AZD7762 to sensitise non-cancerous cells to
gemcitabine. Taken together, these data suggest that select-
ive CHK1 inhibition may potentiate the cytotoxicity of
gemcitabine selectively in tumour cells. Reasons for this
selectivity may include differences in checkpoint function
[34, 35] and p53 regulation [36] between normal cells and
cancer cells. Tumour cells harbouring defects in p53
function lack an efficient G1 checkpoint and thus have to
rely on the S or G2 checkpoints for DNA repair, in which
CHK1/2 have crucial functions [36, 37]. Checkpoint
abrogation can therefore promote DNA-damage-induced
mitotic catastrophe and cell death in p53-defective tumour
cells [38], whereas normal cells may tolerate DNA damage
stress by activating the G1 checkpoint through normal p53
function [35, 36].
AZD7762 did not resensitise gemcitabine-resistant
T24rGEMCI20 cells to gemcitabine when administered at
clinically achievable concentrations. Neither γH2A.X and
53-BP1 focus formation nor phosphorylation of CHK1
was increased in T24rGEMCI20 cells by the investigated
gemcitabine concentrations, indicating a lack of replica-
tion stress and, hence, of the target of CHK1 inhibition.
Accordingly, in a phase I trial conducted in patients with
solid tumours - other than UC - only gemcitabine-naïve
patients responded to the combination of AZD7762 and
gemcitabine [39].
Several findings indicate that p21CIP1 is involved in the
control of DNA repair pathways including homologous
recombination (HR) [40]. p21CIP1 promotes HR by inhibit-
ing cyclin dependent kinases (CDK), since increased CDK
activity in the absence of p21CIP1 is associated with
elevated levels of DNA damage [41]. It has accordingly
been reported that p53/p21CIP1 dual-mutant UCCs display
an enhanced cytotoxic response to genotoxic agents com-
bined with CHK1 inhibition over either p53- or p21CIP1-
deficient cells [25]. Indeed, in the RT-112 cell line, which
has an inactivating mutation in p21CIP1, gemcitabine-
induced double strand breaks persisted longer (Fig. 6) and
the sensitisation to gemcitabine by AZD7762 appeared to
be quantitatively stronger (Fig. 1a) than in other cell lines.
This observation suggests a role for p21CIP1 in DNA repair
in UCCs as well. In the current study, however, CHK1
inhibition by AZD7762 sensitised UCCs to gemcitabine
regardless of their p21CIP1 status and in the T24 cell line
AZD7762 abrogated DNA repair of gemcitabine-induced
DNA double strand breaks (Fig. 5a). These observations
may mean that AZD7762 overcomes the influence of
p21CIP1 on the DNA repair process.
A phase I clinical trial of AZD7762 has been conducted
in patients with solid tumours other than urothelial car-
cinoma but was prematurely terminated due to cardiac
toxicity [39]. Currently, novel inhibitors specific for CHK1
or with broader target specificity are tested in several
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clinical trials [42, 43]. In combination with gemcitabine,
such compounds might prove efficacious with tolerable
toxicity in patients with treatment-naïve advanced bladder
cancers who are ineligible for cisplatin.
Conclusions
The CHK1/2 inhibitor AZD7762 enhanced gemcitabine
activity in gemcitabine-sensitive UCCs through inhibition
of the gemcitabine-induced DNA damage response, which
is predominantly mediated through CHK1 inhibition.
Hence, the current study provides a rationale for the testing
of CHK1 inhibitors or other therapy strategies that interfere
with CHK1 function in combination with gemcitabine in
gemcitabine-naïve UC patients, in particular for patients
with advanced and/or metastatic disease who are ineligible
for cisplatin. Notably, potentiation of gemcitabine effects by
AZD7762 in xenografts from several other cancer types has
been already reported [14, 44, 45]. The next step towards
application of our results in bladder cancer should therefore
be determining the optimal combinations of gemcitabine
and CHK1 inhibitors in animal models of the disease.
Additional files
Additional file 1: Figure S1. Viability in UCCs after sequential
treatment with AZD7762 and gemcitabine. Relative cell viability in several
UCCs was measured by MTT assay (mean ± SD, n = 4) after cells were
sequentially treated (pretreated with AZD7762 for 24 h and then
incubated with gemcitabine for 48 h). (TIF 142 kb)
Additional file 2: Figure S2. Viability in UCCs after combined
treatments with cisplatin, romidepsin or givinostat, and AZD7762. a
Relative cell viability in the T24 and RT-112 cell lines was measured by
MTT assay (mean ± SD, n = 4) after cells were treated for 48 h either with
cisplatin, romidepsin or givinostat combined with AZD7762. b Western
blot analysis of S345 CHK1 after treatments with gemcitabine (10 nM),
cisplatin (5 μM), romidepsin (4 nM) and givinostat (0.5 μM) in T24 cells
(24 and 48 h). As loading control, GAPDH was stained. (TIF 214 kb)
Additional file 3: Figure S3. a, b Immunofluorescence staining of
γH2A.X (green), 53-BP1 (red), and nuclei staining with DAPI (blue) in
VM-CUB1 (a) and RT-112 (b) cells after the indicated treatments. Scale
bar = 50 μm. (TIF 1728 kb)
Additional file 4: Figure S4. a CDKN1A mutations in UCCs. p21CIP1
expression of UCCs was assessed by western blotting with α-tubulin as
loading control. b Induction of p21CIP1 was assessed by western blot analysis
after 24 or 48 h of treatment with gemcitabine and/or AZD7762 in
CDKN1A-wildtype VM-CUB1 and CDKN1A-mutant RT-112 cells. (TIF 126 kb)
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